BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
15.48
+0.22 (+1.44%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close15.26
Open15.82
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.41 - 15.84
52 Week Range12.55 - 21.59
Volume689,832
Avg. Volume690,017
Market Cap60.999B
Beta (5Y Monthly)1.21
PE Ratio (TTM)8.39
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.78 (5.46%)
Ex-Dividend DateApr 28, 2019
1y Target Est26.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer
      Zacks

      The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer

      The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer

    • There’s scant evidence so far for chloroquine as a COVID-19 drug — but there’s already a shortage
      MarketWatch

      There’s scant evidence so far for chloroquine as a COVID-19 drug — but there’s already a shortage

      The millions of doses of chloroquine donated to the federal stockpile can now be used to treat COVID-19 patients. At the same time, pharmacists are concerned that prescribing the drug for the novel coronavirus has created shortages of the medication for patients with lupus and rheumatoid arthritis and raises questions about safety.

    • Reuters

      RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

      Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients. Jakavi is used in adults with bone marrow cancer, or myelofibrosis, among other conditions. Novartis and Incyte want to see if it helps COVID-19 patients suffering from an immune system overreaction, also called a cytokine storm.

    • Bayer says glyphosate settlement talks delayed by coronavirus-Handelsblatt
      Reuters

      Bayer says glyphosate settlement talks delayed by coronavirus-Handelsblatt

      Talks between Bayer AG and plaintiff lawyers to settle claims that the German company's glyphosate-based weedkillers cause cancer have been slowed by the coronavirus pandemic, Bayer's Chief Executive told daily Handelsblatt. Court-appointed mediator Ken Feinberg told Reuters last month that the talks were slowed by the pandemic. In the Handelsblatt interview, CEO Baumann reiterated remarks he made at the end of February that he was under no time pressure to strike a settlement deal and that he would not submit to a schedule or deadline.

    • Coronavirus update: Global case count tops 700K, JNJ announces vaccine candidate
      Yahoo Finance

      Coronavirus update: Global case count tops 700K, JNJ announces vaccine candidate

      The global coronavirus case count surpassed 735,000 Monday, with more than 35,000 deaths reported, according to Johns Hopkins.

    • FDA approves emergency use of malaria pill for COVID-19 treatment
      Yahoo Finance

      FDA approves emergency use of malaria pill for COVID-19 treatment

      The Food and Drug Administration approved the anecdotally promising malaria drug for emergency use to treat hospitalized patients for Covid-19.

    • Reuters

      Merck and Bayer's heart drug vericiguat meets primary efficacy endpoint in Phase 3 study

      Merck & Co Inc said on Saturday that vericiguat, an investigational drug for patients with worsening chronic heart failure, met the primary efficacy endpoint in the VICTORIA trial. The VICTORIA trial is a Phase 3 study evaluating the efficacy and safety of the drug vericiguat, which is being jointly developed with Bayer AG, the company said. Compared with a placebo, the drug reduced the risk of heart failure hospitalization or cardiovascular death in heart failure patients with reduced ejection fraction (HFrEF) when given in combination with available therapies, Merck said.

    • North America farm suppliers race COVID-19 spread for planting season
      Reuters

      North America farm suppliers race COVID-19 spread for planting season

      WINNIPEG, Manitoba/CHICAGO, March 26 (Reuters) - North America's biggest farm suppliers are accelerating shipments of fertilizer, seeds and agricultural chemicals to crop-growing regions in an unprecedented race against the coronavirus that threatens to disrupt planting season. The timing could not be worse for farmers preparing to plant crops. Disruptions in deliveries of fertilizer, seeds or chemicals could reduce harvests and incomes for U.S. farmers who were hoping this year to sell more crops to China under the terms of a trade agreement signed in January.

    • After series of cuts, India axes Bayer's GM cotton royalty
      Reuters

      After series of cuts, India axes Bayer's GM cotton royalty

      India has axed the royalties that local seed companies pay to German drugmaker Bayer AG for Monsanto's genetically modified (GM) cotton, a government order said, after cutting them back since 2016. More than 45 local cotton seed companies pay royalties to Monsanto, acquired by Bayer in 2018, for GM cotton using a gene that produces its own pesticide.

    • Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness
      MarketWatch

      Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness

      President Donald Trump and the Food and Drug Administration commissioner appeared to exchange conflicting statements about how a decades-old antimalaria drug is being used to treat COVID-19.

    • Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown
      MarketWatch

      Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown

      The U.S. is wrapping up the first full business week feeling the brunt of the COVID-19 pandemic, with restaurants, bars, parks, retailers and workplaces shut down in many cities across the nation and three states in lockdown.

    • Good news for the stock market would be any potential treatment against the coronavirus
      MarketWatch

      Good news for the stock market would be any potential treatment against the coronavirus

      President Trump touts chloroquine, which has been controversial. Other drugs may find some success in the weeks or months ahead.

    • Barrons.com

      How to Invest in a Time of Turmoil

      Throw away the old playbook, says Bernstein strategist Inigo Fraser Jenkins. Government policy, not the usual factors such as valuation, will drive the stock market for a while

    • Does ibuprofen make the coronavirus worse? Is it still safe to take aspirin?
      MarketWatch

      Does ibuprofen make the coronavirus worse? Is it still safe to take aspirin?

      This has been another tough pill to swallow: France’s health ministry has suggested that certain painkillers could aggravate the effects of the coronavirus. Olivier Veran tweeted last week that some nonsteroidal anti-inflammatories (aka NSAIDs) worsen the effects of COVID-19, the disease caused by the novel coronavirus. If you have a fever, take paracetamol [aka acetaminophen].

    • MarketWatch

      Teva to donate 6 million doses of hydroxychloroquine, floated as a potential treatment for COVID-19

      Shares of Teva Pharmaceutical Industries Ltd. gained 13% in premarket trading on Friday following a Thursday night announcement that the drugmaker will donate more than 6 million doses of hydroxychloroquine sulfate tablets in the U.S. this month. Chloroquine, a longtime malaria drug that is sometimes used as a treatment for rheumatoid arthritis, is being floated as a potential treatment for people sickened by the novel coronavirus by the Trump administration. Teva said in a news release that the drug, which has not received Food and Drug Administration approval as a treatment for COVID-19, has been requested by government officials in efforts to treat the disease. Bayer AG and Mylan have also said they will produce chloroquine therapies as a result of the COVID-19 pandemic. Teva's stock is down 29.9% year-to-date, while the S&P 500 has dropped 25.4%.

    • MarketWatch

      Bayer donates chloroquine to U.S., to seek emergency use as COVID-19 treatment

      U.S. listed shares of Bayer AG rose 3% in trading on Thursday afternoon after it said it had donated three million tablets of Resochin, a chloroquine product, to the U.S. The German drugmaker said that it is seeking an emergency use authorization for the drug in the U.S., where it is not approved. Health care providers in countries like China and France have been using chloroquine-based therapies to treat COVID-19 patients as there are no proven treatments for the disease. At a news conference on Thursday, President Donald Trump talked up use of the antimalaria drug to treat patients who have the novel coronavirus, and FDA commissioner Stephen Hahn said that while chloroquine has been approved for other indications, it would still need to go through clinical trials. Bayer's stock is down 34% year-to-date, while the S&P 500 has dropped 25%.

    • Reuters

      Potential coronavirus treatment touted by Trump already in shortage -pharmacists

      An old malaria treatment that has been tried with some success against the new coronavirus and was touted by U.S. President Donald Trump at a news briefing earlier on Thursday is in short supply as demand surges amid the fast-spreading outbreak. The American Society of Health-System Pharmacists (ASHP), which maintains a list of drugs in shortage independent of the U.S. Food and Drug Administration's list, added the generic malaria drug hydroxychloroquine to its list on Thursday. The new coronavirus, which causes the highly contagious COVID-19 respiratory illness, emerged in December in Wuhan, China and has spread throughout the world.

    • Reuters

      Bayer donates 3 mln malaria tablets to U.S. for potential use against coronavirus

      Bayer AG said on Thursday it has donated 3 million tablets of the malaria drug Resochin to the U.S. government for potential use to treat COVID-19. Resochin, made of chloroquine phosphate and an approved treatment for malaria, is being evaluated in China for its potential use against COVID-19, the disease caused by the fast-spreading coronavirus. Bayer said the drug is currently not approved for use in the United States and the company is working with appropriate agencies on an emergency use authorization for its use in the United States.

    • Here’s one analyst’s take on the coronavirus drugs for today and the future
      MarketWatch

      Here’s one analyst’s take on the coronavirus drugs for today and the future

      Analysts at Bernstein Research in a comprehensive note discussed what approaches are worth keeping an eye on.

    • Bayer inches toward glyphosate settlement: WSJ
      Reuters

      Bayer inches toward glyphosate settlement: WSJ

      Shares of the German drugs and pesticides company have come under immense pressure since it lost the first U.S. lawsuit claiming that glyphosate-based Roundup, acquired via its takeover of Monsanto in 2018, causes cancer. Bayer had also said that based on average analyst predictions of a settlement worth about $10 billion, the company would not have to write down the value of the $63 billion Monsanto acquisition. The settlement still appears poised to end up around $10 billion, the WSJ report https://www.wsj.com/articles/bayer-advances-toward-resolving-roundup-litigation-11584124255?mod=searchresults&page=1&pos=3 said, citing a person familiar with the matter.